FY22 Results Presentation

Strong growth in operating cashflows A$m FY22 FY21 Growth Statutory operating cashflow 217.1 219.0 (3%) Add: IPO deal costs in operating cash flow 36.3 (1.0) Add: Net finance costs paid 0.2 (0.2) Add: Net income taxes paid 28.3 8.0 Pro forma operating cashflow¹ 281.9 225.8 25% Pro forma EBITDA² 308.0 234.7 31% Pro forma EBITDA cash conversion³ 92% 96% Statutory cashflow Operating cashflow Investing cashflow Financing cashflow Net increase / (decrease) in cash Opening cash (including FX differences) Closing cash 18 | FY22 Results Presentation 217.1 219.0 (3%) (252.2) (1,251.1) 100.9 1,137.9 65.8 105.8 105.6 1.0 171.4 106.8 61% Pro forma operating cashflow increased 25% to $281.9m > Underpinned by EBITDA growth in FY22 Investing cashflow of -$252.2m Acquisitions of Generation Health, DWFS, Early Start Australia, Mylntegra and Mobility, Clustera, Biosymm and Lifecare ($207.3m) Capex driven by Restart Scheme mobilisation, Canadian RSVP ramp-up, IT fleet and security upgrades - $39.6m Financing cash flows of +$100.9m Includes proceeds of $343.5m from the IPO and debt repayments of $167.8m Interest payments down $23.5m following July 2021 debt refinance, IPO and debt repayment (1) pro forma operating cash (statutory operating cash adding back cash income tax paid, net finance costs and one-off IPO and advisory fees) (2) Earnings before interest, tax, depreciation and amortization, refer slide 27 for a reconciliation of pro forma EBITDA (3) Cash conversion reflects pro forma operating cash (statutory operating cash adding back cash income tax paid, net finance costs and one-off IPO advisor fees) divided by pro forma EBITDA. APM enabling better lives

View entire presentation